摘要
丙型肝炎病毒(HCV)感染是引起肝硬化、终末期肝病以及肝细胞癌的重要原因。慢性丙型肝炎的标准化治疗方案———聚乙二醇化干扰素α联合利巴韦林已取得了良好的效果,但进展至肝硬化尤其是失代偿期的患者多难以耐受干扰素的不良反应,给抗病毒治疗带来困难。面对我国丙型肝炎肝硬化比例较高、肝移植实施困难、对标准的抗病毒治疗方案应答率高的特点,参考国际指南,作者在国内率先探索和提出了丙型肝炎肝硬化分级标准及相应的抗病毒治疗策略,并进行了相关的临床研究和应用。依据作者提出的丙型肝炎肝硬化的分级方法,先采取不同的处置方法缓解脾亢或减少副作用后,再采用标准化抗病毒治疗方案,可以有效地延缓肝硬化的进展,减少HCV感染相关并发症,最终提高患者生活质量。
Chronic hepatitis C（CHC） is a major cause of cirrhosis,end-stage liver disease,and hepatocellular carcinoma.The combination drug regimen of pegylated interferon-alpha（PEG-IFNα） and ribavirin is the approved and well-accepted standard-of-care for CHC.However,CHC patients with decompensated cirrhosis usually have contraindications for the use of PEG-IFNα and ribavirin,and the results of therapy are generally poor.To address China＇s high prevalence of hepatitis C virus（HCV）-related cirrhosis,difficulties of implementing liver transplantation,and the higher sustained virological response rate seen in Chinese cirrhotic patients,we developed a grading strategy of antiviral therapy for Chinese patients with HCV-related cirrhosis based upon the clinical practice guidelines published by the American Association for the Study of Liver Diseases（AASLD） and the European Association for the Study of the Liver（EASL）.Clinical application of this strategy demonstrated it to be effective for slowing down the rate of cirrhosis progression,preventing complications of HCV-related liver disease,and improving the patients＇ quality of life.
出处
《临床肝胆病杂志》
CAS
2013年第2期93-96,共4页
Journal of Clinical Hepatology
关键词
肝炎
丙型
慢性
肝硬化
抗病毒治疗
hepatitis C
chronic
liver cirrhosis
antiviral therapy
